Correction to: Comment on: Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsSARS-CoV-2 and COVID-19 Research · COVID-19 Clinical Research Studies · Respiratory viral infections research
This is a correction to: Alexis Lacout, Xavier Azalbert, Corinne Reverbel, Jean-François Lesgards, Dominique Cerdan, Valère Lounnas, Gérard Guillaume, Martin Zizi, Christian Perronne, Comment on: Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial, Journal of Antimicrobial Chemotherapy, Volume 80, Issue 3, March 2025, Pages 891–892, https://doi.org/10.1093/jac/dkae385.
In the originally published version, Dr Martin Zizi’s affiliations were incorrectly indicated. The correct affiliation for Dr Zizi is Aerendir Mobile Inc., Mountain View, CA 94040, USA.
This has been corrected in the published item.